Physician profile
Michael Patrick Hunter
NPI 1386023471
$4,993.96
in general payments reported to CMS, 2019-2025
24 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.39 · 2020: $13.74 · 2021: $116 · 2022: $2,288 · 2023: $859 · 2024: $1,532 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511 · Travel and Lodging: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.47 |
| Travel and Lodging | $987.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $1,628.85 | 2022 | |
| Pulmonx Corporation | $1,024.15 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Glaxosmithkline, LLC. | $564.93 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $500.49 | 2022-2024 | Tezspire, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.18 | 2022-2024 | Ofev |
| Tela Bio, INC. | $146.51 | 2022 | |
| Galvanize Therapeutics, INC | $137.15 | 2024 | Aliya System |
| Gilead Sciences, INC. | $132.62 | 2021-2023 | |
| Mylan Specialty L.P. | $99.22 | 2022-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $66.39 | 2023-2024 | Dupixent |
| Intuitive Surgical, INC. | $64.78 | 2024-2025 | |
| Tonix Medicines, INC. | $58.05 | 2025 | Tonmya |
| Insmed, INC. | $51.16 | 2023-2024 | Arikayce |
| Genzyme Corporation | $42.42 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $31.10 | 2024 | Opsumit, Uptravi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.29 | 2023 | Xarelto |
| Electromed, INC. | $28.39 | 2023 | Smartvest |
| Fisher & Paykel Healthcare INC | $27.25 | 2023 | Fisher & Paykel Healthcare |
| Grifols USA, LLC | $23.80 | 2024 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $21.33 | 2023 | Glassia |
| Acera Surgical, INC. | $18.29 | 2025 | Restrata Wound Matrix |
| Integra Lifesciences Corporation | $15.62 | 2021 | |
| Allergan, INC. | $13.74 | 2020 | |
| Inogen, INC. | $8.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.